Delivery Order SPE2DB22D2007-SPE2DB25FJ1CF

Award Date 4/30/25
Potential Completion Date 5/1/25
Potential Value $18K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract is a firm fixed-price delivery order with a ceiling value of $4,212.40 and a period of performance through April 2025. The contract is not set aside and is open to full and open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $8,424.80. The contract is a firm fixed-price delivery order with an ultimate completion date of April 28, 2025. The contract was not set aside and is open to full and open competition. AmerisourceBergen Drug Corp holds a...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has a ceiling value of $40,781.00 and a completion date of December 3, 2024. It is a firm fixed-price, Delivery Order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, at a ceiling value of $5,054.88. The contract has an ultimate completion date of January 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $18,394.08 and an ultimate completion date of August 11, 2023. The contract is a firm fixed-price delivery order that does not have a set-aside designation, indicating open competition....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The contract has a ceiling value of $9,268.12 and a period of performance through February 14, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds a larger...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,263.72, is for the procurement of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has an ultimate completion date of January 17, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order contract awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $52,789.50 and a completion date of August 10, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $4,212.40. The contract is a firm fixed-price delivery order with an ultimate completion date of April 10, 2025. No set-aside was used for this award. AmerisourceBergen holds a larger $999,999,999...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine. The contract has a total ceiling value of $105,310.00 and a period of performance through January 17, 2025. The contract is a firm fixed price delivery order, with no set-aside designation. AmerisourceBergen holds a significant...
  • SPE2DB22D2007
    Indefinite Delivery Contract
  • SPE2DB22D2007-SPE2DB25FJ1CF
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $17,639.40. The contract is a firm fixed-price delivery order, with a performance period ending on May 1, 2025. This order is not set aside for any specific business type.

AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard.

Generated 7/30/25, 9:55 AM